pharmaphorum
JUNE 29, 2022
COVID vaccines and treatments have created a substantial market over and above the existing Rx market- IQVIA estimates that the cumulative value of COVID vaccines could be between $185 and 295bn to 2026. The initial pandemic lockdowns prevented many patients from seeing doctors face-to-face. Launches, therefore, were happening.
PharmaShots
APRIL 25, 2023
In 2019, Mallinckrodt entered into a collaboration agreement with Silence Therapeutics to develop and commercialize RNAi therapeutics to treat life-threatening unmet diseases. Through the 2019 agreement, Mallinckrodt received the exclusive worldwide license to Silence’s SLN500. R&D Expenditure: $85.1M
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Thyroid Pharmacist
JULY 20, 2023
8] A more recent 2019 study looked at the levels of three important nutrients for thyroid health: iodine, iron, and selenium. [9] And as we’ve seen, even with supplementation, you need to address your root causes to prevent iron supply and demand challenges. Too much iron/ferritin can be a problem. However, when they added 1.5
The Thyroid Pharmacist
JANUARY 20, 2023
Nikolai Lazarev defined adaptogens as “an agent that raises the body’s ability to resist stress by countering undesired stressors, whether physical, chemical, emotional, or biological.” The first case is outlined in a 2019 report by Roberto Vita and his research team, and published in Revista da Associação Médica Brasileira.
ISPE
JULY 6, 2023
1 , 4 A Retrospective Journey In 2015, Vertex’s Orkambi was the first approved drug produced under a CM process for the treatment of cystic fibrosis. Vertex continued to invest in CM with two additional approved drugs—Symdeco/Symkevi in 2018 and Trikafta in 2019—with the same indication. 8 (November/December 2019):26–29.
Expert insights. Personalized for you.
59 
Let's personalize your content